Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endoluminal Sciences Pty. Ltd.

www.endoluminalsciences.com

Latest From Endoluminal Sciences Pty. Ltd.

TAVR Market: Next-Generation Devices Seek To Optimize Outcomes

The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.

Medical Device

Australia’s New South Wales Pumps In Funds To Grow Medical Device Industry

Australia’s New South Wales awarded grants totaling AU$10.3 million as part of a campaign to spur innovation among medical device companies. Chosen from 147 applicants, the grant recipients are Elastagen Pty. Ltd., Endoluminal Sciences Pty. Ltd., HEARworks Pty Ltd., mobiLIFE Pty. Ltd. and Saluda Medical.

Medical Device BioPharmaceutical

Expanding The EVAR Toolbox: A Glimpse Into The Future

The US endovascular abdominal aortic aneurysm repair (EVAR) market is one of the most dynamic device segments in the interventional arena, with growth and innovation driven in large part by an accelerating effort to expand EVAR to a wider patient pool. This movement toward more challenging cases does have a downside in terms of potential complications and uncertain long-term durability as physicians push the envelope of existing technology. However, innovation in this field is continuing at a fairly steady pace, and several important new technologies that could improve the safety and durability of EVAR in more complex anatomy could be introduced in the near future. If these devices live up to their early promise, they are likely to ignite even stronger growth in a market already valued at over $1 billion annually worldwide.

Medical Device

EVAR Market: Challenges, Innovation and Growth

Endovascular aortic aneurysm repair procedures account for the majority of abdominal aortic aneurysm repairs performed in the US, and total worldwide revenues from aortic endograft systems now exceed $1 billion per year. Many believe that continuing improvements in endograft technology will drive EVAR penetration to 90% or beyond within the next five to 10 years. This article first appeared in the April issue of Medtech Insight, April 2011.
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Endoluminal Sciences Pty. Ltd.
  • Senior Management
  • Ashish Mitra, CEO & CTO
    Martin Ng, MD, CMO
  • Contact Info
  • Endoluminal Sciences Pty. Ltd.
    Phone: 2 9209 4213
    4 Cornwallis St., National Innovation
    Ctr., Ste. 145
    Eveleigh, Sydney, NSW 2015
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register